Product Information
ALOGLIPTIN-PIOGLIT 25-15 MG TB is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $4.7314 per EA under NDC 45802035165. Its NADAC has been published 132 times since Nov 23, 2016.
FDA first approved this application on Jan 25, 2013.
Strength
25; 15 mg/1; mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802035165
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA022426FDA Approved
1/25/2013
On Market Since
4/8/2016
Pharmacological Classes
Price Statistics
The NADAC for ALOGLIPTIN-PIOGLIT 25-15 MG TB has been published 132 times since Nov 23, 2016, and over the history we have for it it has declined 26.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.7314 per EA |
|---|---|
| All-time high | $6.4376 (Dec 13, 2017) |
| All-time low | $4.7314 (Sep 23, 2026) |
| 52-week high | $5.5246 |
| 52-week low | $4.7314 |
| Median price | $5.5246 |
| Average price | $5.8845 |
| Largest weekly change | -17.5% (Jul 17, 2024) |
| Weeks tracked | 132 |
| Tracking since | Nov 23, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Alogliptin Benzoate and Pioglitazone hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Alogliptin Benzoate and Pioglitazone hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dipeptidyl Peptidase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ALOGLIPTIN-PIOGLIT 25-15 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for ALOGLIPTIN-PIOGLIT 25-15 MG TB, manufactured by Padagis Israel Pharmaceuticals Ltd, is $4.7314 per EA (NDC 45802035165), effective Sep 30, 2026.
How has the price of ALOGLIPTIN-PIOGLIT 25-15 MG TB changed over time?
Over the history we have for it, the NADAC for ALOGLIPTIN-PIOGLIT 25-15 MG TB has declined 26.5%. It has been tracked across 132 weekly CMS publications since Nov 23, 2016.
What are the highest and lowest recorded NADAC prices for ALOGLIPTIN-PIOGLIT 25-15 MG TB?
Since Nov 23, 2016, the NADAC for ALOGLIPTIN-PIOGLIT 25-15 MG TB has ranged from a low of $4.7314 (Sep 23, 2026) to a high of $6.4376 (Dec 13, 2017), with a median of $5.5246 per EA.
Are there cheaper alternatives to ALOGLIPTIN-PIOGLIT 25-15 MG TB?
No other NADAC-published product currently shares the active ingredient and strength of ALOGLIPTIN-PIOGLIT 25-15 MG TB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ALOGLIPTIN-PIOGLIT 25-15 MG TB?
ALOGLIPTIN-PIOGLIT 25-15 MG TB (NDC 45802035165) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.